3PBIOVIAN and INC partner to expand access to oncology treatments in Colombia through biosimilar development
News and updates
Partnerships & Collaborations
3PBIOVIAN and Universidad CEU San Pablo formalize an alliance to promote the development of new professionals in health biotechnology
Diamante Project
Eleva and 3PBIOVIAN sign strategic GMP manufacturing and technology alliance to boost capacity for Eleva’s platform and pipeline
Rokote Laboratories signs an agreement with 3PBIOVIAN for GMP manufacturing of adenovirus vector-based COVID-19 vaccine
3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.
3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.
Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2
BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1
3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
ANLBIO selected Biovian for manufacturing of AAV-based product for the treatment of Alzheimer’s disease.
3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology
Lokon Pharma AB signs an agreement with Biovian
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a cGMP manufacturing collaboration to develop a new treatment to combat solid tumours
Tenboron Ltd signs an agreement with Biovian for GMP contract manufacturing of a novel boron carrier for treating solid tumors
Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia